

## INSTRUCTION TO AUTHORS

### Aim and scope

*Biosight Journal* is a bi-annual (online) research journal, published by Department of Physiology, University of Karachi. The journal covers authoritative, topical and original research papers and reviews in all areas of physiology which interests a wide range of physiologists and life science researcher. The journal wraps the entire spectrum of physiological processes and research advancements ranging from molecular to organism level, symbolizing an astounding development within an explicit field. Articles presenting mechanism and application of cutting-edge research and techniques are strongly encouraged.

### Article Categories published by Biosight

- Editorial
- Solicited and Unsolicited Review article
- Original full length article
- Brief communication

### Subject Areas:

Areas covered under the scope of journal are not restricted to the below mentioned fields:

- Physiology
- Bioinformatics
- Biophysics
- Developmental biology
- Genomics
- Immunology
- Molecular biology
- Pharmacology
- Proteomics
- Toxicology

### Journal ethics

**Biosight** journal follows the guidelines of Committee On Publication Ethics which gives the standard criteria to attain ethical requirements.



### Submission guidelines

#### Editorial policies

All submitted papers would be preliminary evaluated according to scope of journal. The cover letter is important which helps the Editor in his evaluation. Authors should describe the suitability of paper for publication in the journal. The manuscript will be reviewed by two expert reviewers. Final decisions are made by the editorial board.

#### Authorship Criteria

The authorship of a manuscript requires:

- Significant contributions to conceptualize and design of study;
- Substantial participation in data acquisition, statistical analysis and data interpretation;
- Significant participation in drafting of the article or critical revision;
- Final approval of the article for the publication in the journal.

Corresponding author is required to submit the **Copyright & Authorship Declaration Form** with the submission [Download - Copyright Authorship Declaration Form](#)

### **Disclosure statement**

All authors must divulge their potential conflict of interest at the end of the submitted manuscript before references under heading disclosure statement. If no conflict of interest exists author must state that “all authors declare that they have no potential conflict of interest”

### **Funding**

Biosight journal requires all authors to acknowledge their funding in a consistent fashion under a separate heading. If there is no funding, authors state that “This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors”.

### **Process of Manuscript submission**

All manuscript must be submitted at “[submission@biosight.pk](mailto:submission@biosight.pk)”. The submitted manuscript has not been published in any other journal or not consider presently for publication elsewhere. A manuscript receipt will be acknowledged and a decision about acceptance/ rejection/ revision will be made as soon as possible.

Any inquiry concerning manuscript submission should be directed to: [manager@biosight.pk](mailto:manager@biosight.pk)

## **Instruction**

### **Cover letter**

The cover letter must be submitted along with the manuscript. The cover letter must describe the significance of the study and the statement that “the manuscript has not been previously published and is not currently under consideration by another journal and that all authors have approved of and have agreed to submit the manuscript to this journal”.

### **Manuscript preparation**

#### **1) Presentation and formatting**

- Font: Times New Roman
- Font size: 12-point
- Page numbers included at bottom right corner.
- Use MS word format for article submission.

#### **2) Title page must contain:**

- Manuscript title in capital letters, bold format and 14-points character size.
- Complete names of all authors (First, middle and last name)
- Author’s affiliation with the department(s) and/ or institution(s) to which the work should be credited.
- Name, contact number, email address and postal address of the corresponding author must also be mentioned on the title page.
- Source(s) of support in form of grants, funding and any other form should also be indicated on the title page.

- 3) **Word count** excluding references and abstract.
  - Editorial and brief communication: word count up to 2000 words with 10 references
  - Original article 2000-4000 words should be divided into subsections: Abstract, Key-words, Introduction, Methods, Results, Discussion, Conclusion, References, Tables and Figures. Original article contains up to 25 references.
  - Reviews: The word counts up to 5000 with 75 references.
- 4) **Abstract:** The total number words of abstract should not be more than 250 words for original article and reviews whereas 150 words for brief communication. Abstract should be structured and contain subheadings including background, objective, methods, results and conclusions.
- 5) **Key words:** 6 to 8 words
- 6) **Introduction:** describe brief literature with recent references and also state the purpose and rationale of the study.
- 7) **Methods:** Following aspects should be included:
  - Ethical approval:** All reported studies on human beings and animals must be approved by the responsible committee of ethics (institutional or regional) and must be conducted in accordance with the Helsinki Declaration of 1975, as revised in 2000 ([Click Here](#)). A statement having ethical approval number provided by the ethics committee permission and ethical practices must be included in all research articles under the 'Methods' section.
  - Technical information:** Identify the methods, apparatus (give the manufacturer's name and address in parentheses). Provide the sufficient detail of procedure.
  - Units and Abbreviations:** All abbreviation must be provided in System International (SI). The abbreviations must be defined at their first occurrence.
  - Data analysis:** A brief summary of all statistical measures must be provided in the method section.
- 8) **Results:** Present your results in a logical sequence in the text, tables, and illustrations/figure.
- 9) **Discussion:** Include a summary of key findings with related research studies; Mechanism implicated to your work; Strengths and limitations of the study; Interpretation.
- 10) **Conclusion:** The section should include future research directions.

**11) References:** References must be listed in the numerical system (Vancouver). All references should be numbered sequentially [in square brackets] in the text and listed in the same numerical order in the reference section. The reference numbers must be finalized and the bibliography must be fully formatted before submission.

See below few examples of references listed in the correct Vancouver style

### **Typical Paper Reference**

- [1] Boehm M, Nabel EG. Angiotensin-converting enzyme 2-a new cardiac regulator. *N Engl J Med* 2002; 347: 1795-7.
- [2] SoRelle R. Long reach of the N-terminal of B-type natriuretic peptide. *Circulation* 2002; 106: 9059-63.
- [3] Leone A. Biochemical markers of cardiovascular damage from tobacco smoke. *Curr Pharm Des* 2005; 11: 2199-208.
- [4] Meuillet EJ, Mahadevan D, Vankayalapati H, et al. Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxyphosphatidyl- myo-inositol analogues. *Mol Cancer Ther* 2003; 2: 389-99.

### **Typical Chapter Reference**

- [5] Ban Y, Tomer Y. Endocrine diseases. Graves's and Hashimoto's diseases. In: Oksenberg J, Brassat D, Eds. *Immunogenetics of autoimmune disease*. Medical Intelligence Unit. New York: Landes Bioscience and Springer Science-Business Media 2006; pp. 41-58.
- [6] Astrup P. The arterial wall in atherogenesis. In Cavallero Ed. *Atherogenesis*. Padua: Piccin Medical Books 1965: pp. 77-92.

### **Book Reference**

- [7] Carlson BM. *Human embryology and developmental biology*. 3rd ed. St. Louis: Mosby 2004.
- [8] Rosai J. *Histological typing of tumours of the thymus*. 2nd ed. Berlin and Heidelberg: Springer-Verlag 1999.

### **Edited Book**

- [9] Brown AM, Stubbs DW, Eds. *Medical physiology*. New York: Wiley 1983.

### **Conference Paper and Proceedings**

- [10] Kimura J, Shibasaki H, Eds. Recent advances in clinical neurophysiology. *Proceedings of the 10th International Congress of EMG and Clinical Neurophysiology*; 1995 Oct 15-19; Kyoto, Japan. Amsterdam: Elsevier 1996.
- [11] Cooper R, Cutler J, Desvigne-Nickens P, et al. Disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the National Conference on Cardiovascular Disease Prevention. *Circulation* 2000; 102: 3137-47.
- [12] Chao JT, Theriault A, Gapor A. Delta-tocotrienol is a potent inhibitor of monocyte-endothelial cell adhesion. In: *Cutting edge technologies For sustained competitiveness*. *Proceedings of the 2001 PI POC International palm Oil Congress, Food Technology and Nutrition Conference*, Kuala Lumpur, Malaysia, Aug. 20-22, 2001; pp. 225-34.

### **Journal Article on the Internet**

[13] Aylin P, Bottle A, Jarman B, Elliott P. Paediatric cardiac surgical mortality in England after Bristol: descriptive analysis of hospital episode statistics 1991-2002. *BMJ* [serial on the Internet]. 2004 Oct 9; [cited 2004 October 15]; 329: [about 10 screens]. Available from: ([bmj.bmjournals.com/cgi/content/full/329/7470/825](http://bmj.bmjournals.com/cgi/content/full/329/7470/825))

[14] NCT01013350. Prospective observational long-term safety registry of multiple sclerosis patients who have participated in cladribine clinical trials (PREMIERE). Available at ([clinicaltrials.gov/ct2/show/NCT01013350](http://clinicaltrials.gov/ct2/show/NCT01013350))

### **Book/Monograph on the Internet**

[15] Donaldson MS, Ed. Measuring the quality of health care [monograph on the internet]. Washington: National Academy Press 1999 [cited 2004 Oct 8]. Available from: ([legacy.netlibrary.com](http://legacy.netlibrary.com))

[16] Silva ATA. Ed. Development of compounds potentially active against *Helicobacter pylori*. [monograph on the internet]. Araraquara: School of Pharmaceutical Science, Universidade Estadual Paulista 2008 [cited 2010 July 10]. Available from: ([www.fcfar.unesp.br/posgraduacao/cienciasfarmaceuticas/Disertacoes/2008/antonio\\_tavora-completo.pdf](http://www.fcfar.unesp.br/posgraduacao/cienciasfarmaceuticas/Disertacoes/2008/antonio_tavora-completo.pdf)) [monograph in Portuguese].

Web site/Homepage

[17] HeartCentreOnline [homepage on the Internet]. Boca Raton, FL: HeartCentreOnline, Inc.; c2000-2004 [updated 2004 May 23; cited 2004 Oct 15]. Available from: ([www.heartcentralonline.com](http://www.heartcentralonline.com))

[18] Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF), Global discovery program for novel anti-tuberculosis drugs [homepage on the Internet]. The National Institute of Allergy and Infectious Diseases (NIAID) [cited 2011 Jan10]. Available from: ([www.taacf.org](http://www.taacf.org))

### **Journal with Part/Supplement**

If a journal carries continuous pagination throughout the volume, then the issue number can be omitted.

### **Issue with Supplement**

[19] Glauser TA. Integrating clinical trial data into clinical practice. *Neurology* 2002; 58(12 Suppl 7): S6-12.

[20] Durandy A, Kaveri SV, Kuijpers TW, et al . Intravenous immunoglobulins-- understanding properties and mechanisms. *Clin Exp Immunol* 2009; 158(Suppl 1): 2-13.

### **Volume with Part**

[21] Abend SM, Kulish N. The psychoanalytic method from an epistemological viewpoint. *Int J Psychoanal* 2002; 83(Pt 2): 491-5

[22] O'Riordan JI, Thompson AJ, Kingsley DP, et al . The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. *Brain* 1998; 121(Pt 3): 495-503.

### **Issue with Part**

[23] Ahrar K, Madoff DC, Gupta S, Wallace MJ, Price RE, Wright KC. Development of a large animal model for lung tumors. *J Vasc Interv Radiol* 2002; 13(9 Pt 1): 923-8.

[24] Bluestone JA. Costimulation and its role in organ transplantation. Clin transplant 1996; 10(1 Pt 2): 104-9.

### **Patent**

Pagedas AC, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug.

### **E-citations**

Citations for articles/material published exclusively online or in open access (free-to-view), must contain the accurate Web addresses (URLs) at the end of the reference(s), except those posted on an author's Web site (unless editorially essential), e.g. 'Reference: Available from: URL'.

Some important points to remember:

All references must be complete and accurate.

If the number of authors exceeds six then et al. will be used after six names (the term "*et al.*" should be in italics).

Date of access should be provided for online citations.

Journal names should be abbreviated according to the Index Medicus/MEDLINE.

Punctuation should be properly applied as mentioned in the examples given above.

Superscript in the in-text citations and reference section should be avoided.

Abstracts, unpublished data and personal communications (which can only be included if prior permission has been obtained) should not be given in the references section. The details may however appear in the footnotes.

### **12) Tables**

- All tables are numbered in Arabic numerals, consecutively in the order of their first citation in the text and provide a brief title for each table
- Table citation should be provided at the relevant place in text section.
- The tables should be submitted in separate file with their numbers in MS format.
- Provide explanations about the table in footnotes

### **13) Illustrations/ Figures:** provide good quality color scale images/figures. Image of high resolution should be submitted, Dimensions should be 828 x 473 (width x height). Figures/ illustration should be submitted in a separate file.

- Figures should be numbered consecutively according to the order at which they cited first in the text.
- All figures Labels, numbers and symbols should be clearly cited in the text. All figures should be of uniform size. The labeling of figures should be large enough to be readable.
- The color of the symbols, arrows, or letters used in figures should contrast with the background.
- Titles and description of the figure should be given in legends.
- If a figure has been published elsewhere, acknowledge the original source and add reference of that figure with written permission of usage form publisher.

### **Upon acceptance and publication**

Upon acceptance of manuscripts after peer review process, the corresponding author will receive acceptance letter. The manuscript will be processed for publication after APC has been received. All manuscripts will be available online after publishing process.

### **Article Publishing/ Processing Charges (APCs)**

If your manuscript is accepted for publication after peer review, a one-time APC is payable which covers the publication cost and ensures that the article will be freely available online.

An APC for Biosight journal is 2500 PKR for Pakistani authors whereas 150 \$ for foreign authors. If no financial support exists, authors may apply for a waiver at [waiver@biosight.pk](mailto:waiver@biosight.pk).